BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.
Innovating Medicine by Leveraging Artificial Intelligence
We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform in an effort to reduce therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.
Our Differentiated Approach
Therapeutic Area Focus
Targeting neuroscience disorders and immuno-oncology with significant unmet medical need and large market opportunity
The proprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidates
Higher Probability of Success
Developing first-in-class drug candidates while aiming for a higher probability of clinical and regulatory success
Potential to provide clinical benefit to patients in need